期刊文献+

RANKL与骨代谢 被引量:2

RANKL and bone metabolism
下载PDF
导出
摘要 核因子κB受体活化因子配基(receptor activator of NF-κB Ligand,RANKL)是一种Ⅱ型跨膜蛋白,是目前发现的惟一具有诱导破骨细胞分化、发育、发挥功能的因子。NF-κB受体激活子(receptor activatorof NF-κB,RANK)是一种Ⅰ型跨膜蛋白,是RANKL的惟一受体,是RANKL发挥功能的关键。骨保护蛋白(osteoprotegerin,OPG)是一种分泌型糖蛋白,与RANKL竞争性与RANK结合抑制骨吸收、促进骨形成。近年来通过许多对RANKL的研究发现,它不仅在骨质疏松症的发病中起重要作用,而且也在骨代谢过程中受多种因素影响,并为骨质疏松症及其他骨骼疾病的治疗开辟了广阔的前景。 Receptor activator of NF-KB Ligand, a type II transmembrane protein, is so far the only one factor that can induce differentiation, maturation of osteoclastgenesis and mediating its function. Receptor activator of NF-t^B, a type ] transmembrane protein, is the unique receptor of RANKL, and it is very key for RANKL to educe function. Osteo- protegerin is a secretary glucoprotein which can link to RANK and inhibit bone resorption, enhance bone formation. Recently, many studies indicate that RANKL can not only play an important role in the pathogenesis of osteoporosis, but al- so be influenced by many factors, and open up broad prospect for the therapy of osteoporosis and other bone diseases.
出处 《中华骨质疏松和骨矿盐疾病杂志》 2010年第1期59-63,共5页 Chinese Journal Of Osteoporosis And Bone Mineral Research
基金 河北省自然科学基金项目编号C2009001179 河北省医学适用技术跟踪项目(编号GL200839)
关键词 RANKL RANK OPG DENOSUMAB RANKL RANK OPG denosumab
  • 相关文献

参考文献23

  • 1Y. Y. Yuan,P. J. Kostenuik,M. S. Ominsky,S. Morony,S. Adamu,D. T. Simionescu,D. M. Basalyga,F. J. Asuncion,T. A. Bateman.Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease[J]. Osteoporosis International . 2008 (5)
  • 2Jian-min Liu,Hong-yan Zhao,Guang Ning,Ying Chen,Lian-zhen Zhang,Li-hao Sun,Yong-ju Zhao,Man-yin Xu,Jia-lun Chen.IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women[J]. Journal of Bone and Mineral Metabolism . 2008 (2)
  • 3H.-Y. Zhao,J.-M. Liu,G. Ning,Y.-J. Zhao,Y. Chen,L.-H. Sun,L.-Z. Zhang,M.-Y. Xu,J.-L. Chen.Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women[J]. Osteoporosis International . 2008 (2)
  • 4Neveen A. T. Hamdy MD.Osteoprotegerin as a potential therapy for osteoporosis[J]. Current Rheumatology Reports . 2006 (1)
  • 5Huang H,Chang EJ,Ryu J,et al.Induction of c-Fos and NFATcl during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochemical and Biophysical Research Communications . 2006
  • 6Kim T,Kim K,Lee SH,et al.Identification of LRRc17 as a negative regulator of receptor activator of NFkB ligand (RANKL)-induced osteoclast differentiation. Journal of Biochemistry . 2009
  • 7Hikata T,Takaishi H,Hakozaki A,et al.PIAS3 negatively regulates RANKL-mediated osteoclastogenesis direcdy in osteoclast precursors and indirectly via osteoblasts. Blood . 2009
  • 8Bai YD,Yang FS,Xuan K,et al.Inhibition of RANK/ RANKL signal transduction pathway:A promising approach for osteoporosis treatment. Medical Hypotheses . 2008
  • 9Kim H,Choi HK,Shin JH,et al.Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. Clinical Investigator . 2009
  • 10Poblenz AT,Jacoby JJ,Singh S,et al.Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6decoy peptides. Biochemical and Biophysical Research Communications . 2007

同被引文献22

  • 1叶超群,纪树荣,钟兴明.RANKL-RANK-OPG骨调节轴[J].首都体育学院学报,2006,18(6):61-64. 被引量:12
  • 2王冰,曹新生,吴燕红,杨志,张舒.模拟失重对骨形态发生蛋白2(BMP-2)诱导的ROS17/2.8细胞中ERK活性的影响[J].航天医学与医学工程,2006,19(6):399-402. 被引量:3
  • 3BOYLE W J,SIMONET W S,LACEY D L. Osteoclast differ- entiation and activation[J]. Nature, 2003,423 (6937) : 337-342.
  • 4CAO J, VENTON L, SAKATA T, et al. Expression of RA-NKL and OPG correlates with age- related bone loss in maleC57BL/6 mice[J]. J Bone Miner Res, 2008,18 ( 2 ) : 270-277.
  • 5HOFBAUER LC, KHOSLAS, DUNSTANCR, et al. Es-trogen stimu- lates gene expression and protein production of osteoprotegerin in hu- man osteoblastic cells[J].Endocrinology, 1999,140(9) : 4367-4370.
  • 6VIDALNO, BRNDSTREMH, JONSSONKB, et al. Ost-eoprotegerin mRNA is expressed in primary humanosteoblast like cells: downregu- lation by glucocorticoids[J].J Endocrino, 2009,159( 1 ) : 191-195.
  • 7JONES D H, KONG Y-Y, PENNINGER J M. Role of rankl and rank in bone loss and arthritis [J]. Annals of the Rheumatic Diseases, 2012,61 (Suppl 2) :32-39.
  • 8HAYNES D R, CROTI'I T N, LORIC M, et al. Osteoprotegerin and receptor activator of nuclear factor kappa : ligand (RANKL)regulate osteoclast formation by cells in the humanrheumatoid arthritic joint[J]. Rheumatology, 2011,40 ( 6 ) : 623-630.
  • 9Sangala Jaypal, Reddy, Dakwar Elias,et al.Nonsurgical manage- ment of ankylosing spondylitis[J].Neurosurg Focus, 2008,24( 1 ) : 5.
  • 10Nobuhiro Sasaki, Eiji Kusano, Yasuhiro Ando, et al. Glucocorticoid decreases circulat -ing osteoprotegerin (OPG) : possible mechanism for glucocorticoid in-duced osteoporosis.Nephrol[J]. Dial. Transplant, 2011,16:479-482.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部